The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05983198
Recruitment Status : Recruiting
First Posted : August 9, 2023
Last Update Posted : February 28, 2024
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 28, 2026
Estimated Study Completion Date : August 28, 2026